Nicolle Lindsay E
Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.
J Am Geriatr Soc. 2002 Jul;50(7 Suppl):S230-5. doi: 10.1046/j.1532-5415.50.7s.3.x.
Antimicrobial susceptibility of bacteria causing urinary tract infection (UTI) has evolved over several decades as antimicrobial exposure has repeatedly been followed by emergence of resistance. Older populations in the community, long-term care facilities, or acute care facilities have an increased prevalence of resistant bacteria isolated from UTI. Resistant isolates are more frequent in long-term care populations than the community. Resistant isolates include common uropathogens, such as Escherichia coli or Proteus mirabilis, and organisms with higher levels of intrinsic resistance, such as Pseudomonas aeruginosa or Providencia stuartii. Isolation of resistant organisms is consistently associated with prior antimicrobial exposure and higher functional impairment. The increased likelihood of resistant bacteria makes it essential that a urine specimen for culture and susceptibility testing be obtained before instituting antimicrobial therapy. Therapy for the individual patient must be balanced with the possibility that antimicrobial use will promote further resistance. Antimicrobial therapy should be avoided unless there is a clear clinical indication. In particular, asymptomatic bacteriuria should not be treated with antimicrobials. Where symptoms are mild or equivocal, urine culture results should be obtained before initiating therapy. This permits selection of specific therapy for the infecting organism and avoids empiric, usually broad-spectrum, therapy. Where empirical therapy is necessary, prior infecting organisms should be isolated, and recent antimicrobial therapy, as well as regional or facility susceptibility patterns, should be considered in antimicrobial choice. Where empirical therapy is used, it should be reassessed 48 to 72 hours after initiation, once pretherapy cultures are available.
几十年来,随着抗菌药物的反复使用导致耐药性的出现,引起尿路感染(UTI)的细菌对抗菌药物的敏感性不断演变。社区、长期护理机构或急性护理机构中的老年人群,从UTI中分离出的耐药细菌患病率增加。长期护理人群中的耐药菌株比社区中更常见。耐药菌株包括常见的尿路病原体,如大肠杆菌或奇异变形杆菌,以及固有耐药性较高的微生物,如铜绿假单胞菌或斯氏普罗威登斯菌。耐药菌的分离始终与先前的抗菌药物暴露和更高的功能损害有关。耐药细菌可能性的增加使得在开始抗菌治疗之前获取用于培养和药敏试验的尿液标本至关重要。对个体患者的治疗必须与抗菌药物使用会促进进一步耐药的可能性相平衡。除非有明确的临床指征,否则应避免使用抗菌治疗。特别是,无症状菌尿不应使用抗菌药物治疗。在症状轻微或不明确的情况下,应在开始治疗前获得尿培养结果。这允许选择针对感染病原体的特异性治疗,并避免经验性的、通常是广谱的治疗。在需要经验性治疗的情况下,应分离先前的感染病原体,并在选择抗菌药物时考虑近期的抗菌治疗以及区域或机构的药敏模式。在使用经验性治疗时,一旦获得治疗前培养结果,应在开始治疗后48至72小时重新评估。